The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2016 | Strategies to reduce graft-versus-host disease (GvHD)
At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, Miguel Perales, MD, from Memorial Sloan Kettering Cancer Center, New York, NY, discusses strategies to reduce graft-versus-host disease (GvHD), highlighting ex vivo T-cell depletion. An ablative conditioning regimen combined with ex vivo T-cell depletion using CD34 selection offers long-term survival in patients with significantly reduced acute and chronic GvHD and low risk of relapse in acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
